Professor Michael Haude, director of Medical Clinic I at Rheinland Klinikum Neuss Lukaskrankenhaus, performing a PCI using the Robocath R-One robotic catheter guidance system.
January 21, 2020 – Robocath, a company that designs, develops and commercializes cardiovascular robotic systems for the treatment of vascular diseases, announced it has successfully completed its first robotic coronary angioplasties with its R-One robotic catheter guidance system in Germany. The Percutaneous coronary interventions (PCI) were performed by Professor Michael Haude, director of Medical Clinic I at Rheinland Klinikum Neuss Lukaskrankenhaus, and his team.
“I’m proud to be the first user of this brand new European robotic solution for PCI in Germany," Haude said. "These robotic interventions pave the way for a new era in interventional cardiology. The benefits brought by R-One are huge for practitioners and will drastically improve our working conditions, which will consequently benefit patient care. My team and I look forward to integrating this robotic-assisted platform for PCI into our day-to-day clinical practice.”
"Professor Haude has over 30 years experience in interventional cardiology and we rely on capitalizing on this kind of experience to develop clinical evidence and demonstrate all the benefits of our solution," said Philippe Bencteux, chairman and founder of Robocath.
These first procedures in Germany are an important strategic step, said Lucien Goffart, CEO of Robocath. He said interest from major industry players is a clear indicator of this, such as the recent purchased of Corindus by Siemens in 2019.
Founded in 2009 by Philippe Bencteux, M.D., Robocath designs, develops and commercializes robotic solutions to treat cardiovascular diseases. Its solutions aim to make medical procedures safer with reliable technologies, while complementing manual interventions.
R-One is the first solution developed by Robocath. It is designed to operate with precision and perform specific movements, creating better interventional conditions. It uses an open architectureto make it compatible with market-leading devices and cath labs.
The system received European CE mark in February 2019 and started its clinical use in September 2019.
The company hopes to develop a remote treatment system for vascular emergencies.
For more information: www.robocath.com